Ads
related to: fda approved intrathecal drugs for prostate cancer patients advice based- XTANDI® Outcomes
Read XTANDI Patient
Reported Outcomes
- Important Safety Info
Safety Profile & Adverse Reactions
For XTANDI® (enzalutamide).
- XTANDI® EMBARK Data
Review Xtandi EMBARK Trial Data and
Results.
- Prescribing Information
View Prescribing Information
For XTANDI® (enzalutamide).
- XTANDI® Outcomes
Search results
Results from the WOW.Com Content Network
Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). [11]
Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. [1] [2] It is used in the form padeliporfin di-potassium.[2]The most common side effects include problems with urinating (pain, inability to pass urine, strong urge to pass urine, frequent urination, and incontinence), sexual problems (erectile dysfunction and ejaculation failure), blood in ...
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC. [ 11 ] [ 12 ] [ 2 ] [ 13 ] [ 1 ] Shortly afterward, sipuleucel-T was added to the compendium of cancer treatments published by the National Comprehensive Cancer Network (NCCN) as a "category ...
Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
Ads
related to: fda approved intrathecal drugs for prostate cancer patients advice based